Results 1 to 10 of about 12,608 (240)
Varenicline for smoking cessation [PDF]
BMJ, 2007 What can we learn from the story so far? The public health burden of smoking is so enormous it is not surprising that varenicline—the most recently approved drug for smoking cessation—has been prescribed so widely and discussed extensively. A linked paper by Svanstrom and colleagues (doi:10.1136/bmj.e7176) further explores the association between use
Serena Tonstad
+16 more sources
Varenicline: quantifying the risk [PDF]
Canadian Medical Association Journal, 2011 We agree that there is a lack of clarity in Singh and colleagues’ article; it is very difficult for readers to follow how the various assumptions and extrapolations have been made.[1][1] The rather alarming figure of a 72% increase in serious cardiovascular events has been picked up by the ...
Edward N. Squire
+23 more sources
Varenicline for Tobacco Dependence [PDF]
New England Journal of Medicine, 2008 A 57-year-old man with a 60-pack-year history visits his primary care provider because he wants to quit smoking. He has a history of stable coronary artery disease, peripheral vascular disease, and hypertension. He also has severe obstructive lung disease (forced expiratory volume in 1 second, 39% of the predicted value) with a progressive increase in ...
J. Taylor Hays, Jon O. Ebbert
openalex +4 more sources
Brazilian Journal of Medical and Biological Research, 2021 The beneficial effects of drugs that act via nicotinic acetylcholine receptors (nAChRs) on Parkinson's disease (PD) symptomatology may explain the negative correlation between cigarette smoking and risk of this neurological condition.
A. Ribeiro-Carvalho +6 more
doaj +2 more sources
Modulation of cardiomyocyte contractility and action potentials with chemogenetic chloride currents. [PDF]
J PhysiolAbstract figure legend Pluripotent stem cell derived‐cardiomyocytes expressing the chemogenetic tools PSAM‐GlyR and PSAM4‐GlyR were used to generate engineered heart tissue. PSAM‐GlyR and PSAM4‐GlyR activation modulated cardiomyocyte action potentials and contractility. Created in BioRender.com. Abstract Transient perturbation of electrical activity is
Sönmez M +13 more
europepmc +2 more sources
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
Patient Preference and Adherence, 2010 Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, Eric W Klee, Richard D HurtMayo Clinic College of Medicine, Rochester, MN, USAAbstract: Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a ...
Jon O Ebbert +3 more
doaj +3 more sources
Varenicline in the treatment of tobacco dependence
Neuropsychiatric Disease and Treatment, 2008 Karl Fagerström1, John Hughes21Smokers Information Centre, Fagerström Consulting AB, Berga Alle 1, 25452 Helsingborg, Sweden; 2University of Vermont, Burlington, Vermont, USAAbstract: Varenicline, a partial agonist of α4& ...
Karl Fagerström, John Hughes
doaj +5 more sources
Evaluation of the cardiovascular effects of varenicline in rats
Drug Design, Development and Therapy, 2015 Engin Burak Selçuk,1 Meltem Sungu,2 Hakan Parlakpinar,3 Necip Ermiş,4 Elif Taslıdere,5 Nigar Vardı,5 Murat Yalçinsoy,6 Mustafa Sagır,3 Alaaddin Polat,7 Mehmet Karatas,8 Burcu Kayhan-Tetik11Department of Family Medicine, 2Inonu University ...
Selçuk EB +10 more
doaj +6 more sources
Smoking cessation therapy with varenicline
International Journal of COPD, 2008 Uma M Mohanasundaram, Rajinder Chitkara, Ganesh KrishnaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, CA, USAAbstract: Smoking cessation is the only available intervention proven to halt ...
Uma M Mohanasundaram +2 more
doaj +5 more sources